Every Form 4 that Eli Lilly and Company (LLY) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow LLY and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full LLY filings page.
ELI LILLY & Co (LLY) reported that director Gabrielle Sulzberger acquired a small additional position in common stock through a compensation-related award. On September 21, 2026, she received 4.2565 shares credited at $1,164.89 per share, bringing her directly held total to 3,012.4473 shares. Per her election, this award has been deferred into stock units under the Lilly Directors' Deferral Plan and will be settled in common shares after her separation from service.
ELI LILLY & Co (LLY) director Juan R. Luciano reported an acquisition of 13.6637 shares of common stock on September 21, 2026, as a grant/award valued at $1,164.89 per share. Under the Lilly Directors' Deferral Plan, these shares are deferred as stock units and will be settled in common stock after his separation from service, bringing his directly held equivalent position to 16,956.8138 shares.
ELI LILLY & Co (LLY) reported that director J. Erik Fyrwald acquired an award of 8.513 shares of common stock on September 21, 2026, valued at $1,164.89 per share. Following this grant, Fyrwald’s directly held position is 75,536.1308 shares, which have been deferred as stock units under the Lilly Directors' Deferral Plan and will be settled in shares after his separation from service.
ELI LILLY & Co (symbol: LLY) is the issuer of record for a Form 4 filing submitted to the SEC. Alvarez Ralph reported acquisition or exercise transactions in this Form 4 filing.
ELI LILLY & Co (LLY) director Ralph Alvarez reported an automatic grant of 10.6591 shares of common stock on September 21, 2026, valued at $1,164.89 per share. At Mr. Alvarez’s election, this award was deferred as stock units under the Lilly Directors' Deferral Plan, to be settled in shares after his separation from service. Following this grant, he holds 55,838.2192 shares directly and 758 shares indirectly through a trust, for which he disclaims beneficial ownership except for his pecuniary interest.
ELI LILLY & Co (LLY) executive Melissa Seymour, EVP, Global Quality, reported two bona fide gifts of Eli Lilly common stock. She gifted 12 shares on September 9, 2026, and 17 shares on September 22, 2025. The 2025 gift was disclosed as having been inadvertently not reported at the time. No Rule 10b5-1 trading plan is reported.
ELI LILLY & Co (LLY) executive Edgardo Hernandez, EVP & President, Manufacturing Operations, reported a bona fide gift of 13 shares of common stock on September 2, 2026. After this gift, he held 46,082.717 shares directly and 874.220 shares indirectly through a 401(k) account.
No transactions were reported under a Rule 10b5-1 trading plan.
ELI LILLY & Co (LLY) reported that executive vice president and chief people officer Eric Dozier made a bona fide gift of 216 shares of common stock on September 2, 2026. After this gift, he held 14,239.212 shares directly and 413.44 shares indirectly through a 401(k) plan. No transactions were reported under a Rule 10b5-1 trading plan.
ELI LILLY & Co (LLY) director Gabrielle Sulzberger reported an acquisition of 4.1908 shares of common stock on August 17, 2026, as a grant/award. According to the director deferral plan, the value was deferred as stock units in lieu of cash compensation and will be settled in shares after her separation from service, bringing her directly held equivalent share balance to 3003.9096 shares.
ELI LILLY & Co (LLY) director Juan R. Luciano reported the acquisition of 13.4527 shares of common stock on 2026-08-17 through a grant/award. According to the deferral election, these shares have been credited as stock units under the Lilly Directors' Deferral Plan in lieu of cash compensation and will be settled in common stock after his separation from service. Following this award, his directly owned position is reported as 16,918.0448 shares.
ELI LILLY & Co (symbol: LLY) is the issuer of record for a Form 4 filing submitted to the SEC.
ELI LILLY & Co (LLY) director Ralph Alvarez reported an acquisition of common stock as compensation. On 2026-08-17, he received 10.4945 shares valued at $1183.16 per share, granted as deferred stock units under the Lilly Directors' Deferral Plan, to be settled in shares after he leaves board service. Following this, he holds 55,744.788 shares directly and 758 shares indirectly through a trust, for which he disclaims beneficial ownership beyond his pecuniary interest.
ELI LILLY & Co (LLY) executive Patrik Jonsson, EVP & President, LLY International, reported selling 6,500 shares of common stock on 2026-08-17 at $1,175.10 per share in an open-market or private transaction. After this sale, he directly holds 54,146.62 shares and has an additional 632.40 shares held indirectly through a 401(k) plan. The sale was carried out under a Rule 10b5-1 trading plan adopted on February 17, 2026.
ELI LILLY & Co officer Donald A. Zakrowski, SVP, Finance, & CAO, reported selling 2,000 shares of common stock on 2026-08-10 at an average price of $1,185.01 per share in an open-market transaction. After this sale, he held 1,525.89 shares directly and 1,734.73 shares indirectly through a 401(k). The sale was effected pursuant to a Rule 10b5-1 trading plan adopted on May 11, 2026.
ELI LILLY & Co executive Anat Hakim, EVP, GC & Secretary, reported a sale of 5,000 shares of common stock on August 7, 2026 at $1,190.00 per share. The shares were held indirectly through her spouse, and she disclaims beneficial ownership except to the extent of her pecuniary interest. The transaction was effected under a Rule 10b5-1 trading plan adopted on February 10, 2026. After the sale, 11,875 shares remained held indirectly by her spouse, 22,987.024 shares were held directly, and 15,700 shares were held indirectly through the Anat Hakim SLAT.
ELI LILLY & Co executive Melissa Seymour, EVP Global Quality, exercised 981 restricted stock units into an equal number of common shares on August 1, 2026. To satisfy exercise price or tax obligations, 438.707 shares were withheld at $1,148.8400 per share, and 952 RSUs remain scheduled to vest on August 1, 2027.
ELI LILLY & Co director Gabrielle Sulzberger reported a grant/award acquisition of 4.3232 shares of common stock on July 20, 2026 at $1,146.90 per share. At her election, this amount was deferred as stock units under the Lilly Directors' Deferral Plan and will be settled in shares after her separation from service. Following this award, she directly holds 2,999.7188 shares of Eli Lilly common stock.
LUCIANO JUAN R reported acquisition or exercise transactions in this Form 4 filing.
ELI LILLY & Co director Juan R Luciano received a grant of 13.878 shares of common stock on 2026-07-20 at $1,146.9000 per share. These shares were deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan and will be settled in common shares after his separation from service. Following this award, he directly holds 16,904.5921 shares.
Fyrwald J Erik reported acquisition or exercise transactions in this Form 4 filing.
Eli Lilly director J Erik Fyrwald elected to receive 8.6465 shares’ worth of common stock on July 20, 2026 as deferred stock units in lieu of cash director compensation at $1,146.90 per share, bringing his direct holdings to 75,409.7433 shares, to be settled after his separation from service.
Alvarez Ralph reported acquisition or exercise transactions in this Form 4 filing.
ELI LILLY & Co director Ralph Alvarez received an award of 10.8263 common shares on 2026-07-20, valued at $1146.9000 per share. At his election, the award was deferred as stock units under the Lilly Directors' Deferral Plan, to be settled in shares after separation from service. Following this grant, he holds 55734.2935 shares directly and 758.0000 shares indirectly through a trust, for which he disclaims beneficial ownership beyond his pecuniary interest. The report indicates the transaction was not made under a Rule 10b5-1 trading plan.
ELI LILLY & Co director Gabrielle Sulzberger received a stock-based compensation award rather than making an open-market trade. She acquired 4.3904 shares of common stock on an award basis at $1,129.35 per share, bringing her direct holdings to 2,995.3956 shares.
According to the company’s directors’ deferral program, she elected to defer this compensation into stock units under the Lilly Directors' Deferral Plan. These units will be settled in shares of common stock after she separates from board service, so this filing reflects a deferred equity award, not a cash salary payment or market purchase.
ELI LILLY & Co director Juan R. Luciano received a grant of 14.0937 shares of common stock at $1,129.35 per share. At his election, this award has been deferred as stock units under the Lilly Directors' Deferral Plan and will be settled in shares after his separation from service. Following this compensation-related acquisition, his direct holdings total 16,890.7141 shares of common stock.
Fyrwald J Erik reported acquisition or exercise transactions in this Form 4 filing.
ELI LILLY & Co director J Erik Fyrwald received a grant of 8.7809 shares of common stock equivalent on a deferred basis. The award was priced at $1,129.35 per share and was taken in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan. After this grant, Fyrwald holds a total of 75,401.0968 shares of Lilly common stock directly, including these deferred stock units, which will be settled in shares after his separation from service.
ELI LILLY & Co director Ralph Alvarez reported a compensation-related stock award, increasing his direct holdings. On June 15, 2026, he acquired 10.9945 shares of common stock at $1,129.35 per share, characterized as a grant or award rather than an open-market purchase.
According to the footnotes, these shares were deferred as stock units under the Lilly Directors' Deferral Plan in lieu of cash compensation and will be settled in common stock after he leaves the board. Following this award, Alvarez directly holds 55,723.4672 shares of common stock and indirectly holds 758 shares through a trust, where he disclaims beneficial ownership beyond his pecuniary interest.
ELI LILLY & Co executive Ilya Yuffa reported an insider sale of company stock. On June 10, 2026, Yuffa, EVP & President, LLY USA & Global Capabilities, completed an open-market sale of 2,500 shares of Eli Lilly common stock at an average price of $1,150.77 per share.
The transaction was carried out under a Rule 10b5-1 trading plan that Yuffa adopted on February 13, 2026, indicating it was pre-arranged. Following this sale, he directly holds 29,804.111 shares of Eli Lilly common stock.
ELI LILLY & Co director Gabrielle Sulzberger received a stock award equivalent to 5.018 shares of common stock, valued at $988.09 per share. The award was not a market purchase but a grant reported as an acquisition.
According to the disclosure, Sulzberger elected to defer this compensation into stock units under the Lilly Directors' Deferral Plan, instead of taking cash. These stock units will be settled in shares of common stock after her separation from service. Following this grant, her directly held and reported common stock interest totals 2,986.617 shares.
LUCIANO JUAN R reported acquisition or exercise transactions in this Form 4 filing.
ELI LILLY & Co director Juan R. Luciano received an equity award of 16.109 shares of common stock on May 18, 2026, valued at $988.09 per share. According to the filing, he elected to defer this grant into stock units under the Lilly Directors' Deferral Plan, to be settled in shares after his separation from service. Following this award, he directly holds 16,850.832 shares of Lilly common stock.
ELI LILLY & Co director J Erik Fyrwald reported a compensation-related stock award, not an open-market trade. He acquired 10.036 shares of common stock on May 18, 2026 at a reference price of $988.09 per share through a grant.
Under the Lilly Directors' Deferral Plan, he elected to defer this award as stock units, to be settled in common shares after his separation from service. Following this grant, his direct holdings increased to 75,279.592 shares of Lilly common stock.
ELI LILLY & Co director Ralph Alvarez reported an acquisition of 12.566 shares of common stock at $988.0900 per share as a grant or award. At his election, this amount was deferred as stock units under the Lilly Directors' Deferral Plan and will be settled in shares after his separation from service. Following the transaction, he directly holds 55,627.279 shares of common stock and indirectly holds 758 shares by trust, while disclaiming beneficial ownership except to the extent of his pecuniary interest.
Lilly Endowment Inc, a former 10% shareholder of ELI LILLY & Co, sold a total of 15,828 shares of common stock in open-market transactions. The sales occurred at weighted average prices of about $995.23 and $996.18 per share, with execution prices ranging from $995.00 to $996.46. After these transactions, Lilly Endowment continues to hold about 91,881,150 shares of Eli Lilly common stock.
Eli Lilly & Co director Gabrielle Sulzberger received a compensation-related stock grant rather than buying shares on the market. On this award, she acquired 5.39 shares of common stock at $919.90 per share, bringing her direct holdings to 2,981.599 shares.
According to the disclosure, she elected to defer this grant into stock units under the Lilly Directors' Deferral Plan. These units will be settled in Eli Lilly common stock after she separates from board service, turning current cash compensation into future share-based value.
ELI LILLY & Co director Juan R. Luciano received a small stock grant. He acquired 17.3030 shares of common stock as a grant or award at a reported price of $919.9000 per share. After this transaction, he directly holds a total of 16,834.7230 Eli Lilly common shares.
ELI LILLY & Co director J Erik Fyrwald reported a compensation-related stock award rather than an open-market trade. He acquired 10.78 shares of common stock at $919.90 per share through a grant classified as a “grant, award, or other acquisition.”
According to the footnote, he elected to defer cash compensation into stock units under the Lilly Directors' Deferral Plan, to be settled in shares after his separation from service. Following this grant, his direct holdings total 75,269.556 Lilly common shares.
ELI LILLY & Co director Ralph Alvarez increased his equity-based compensation exposure through a deferred stock award. He acquired 13.498 shares of common stock equivalent as a grant or award at $919.90 per share, electing to defer cash compensation into stock units under the Lilly Directors' Deferral Plan.
After this award, his directly held common stock totaled 55,614.713 shares, with an additional 758 shares held indirectly by a trust. The deferred stock units will be settled in shares of common stock following his separation from service, and he disclaims beneficial ownership except to the extent of his pecuniary interest.
ELI LILLY & Co director Gabrielle Sulzberger reported a small stock-based compensation grant. She acquired 5.013 shares of common stock on March 16, 2026 at a price of $989.12 per share through a grant or award rather than an open-market purchase.
According to the disclosure, she elected to defer these shares as stock units under the Lilly Directors' Deferral Plan, to be settled in common stock after she separates from service. Following this grant, she directly holds a total of 2,976.209 shares of Eli Lilly common stock.
Eli Lilly & Co director Juan R. Luciano received a stock-based compensation award rather than cash fees. On 2026-03-16, he acquired 16.092 shares of common stock at $989.12 per share as a grant or award. Following this transaction, he directly holds 16,817.420 shares of Eli Lilly common stock.
According to the company’s directors’ deferral plan, these shares have been deferred as stock units in lieu of cash compensation and will be settled in actual shares of common stock after Luciano separates from service as a director.
ELI LILLY & Co director J. Erik Fyrwald reported a small stock-based compensation grant. He acquired 10.026 shares of common stock valued at $989.12 per share, increasing his direct holdings to 75,258.776 shares.
The filing notes he elected to defer this award into stock units under the Lilly Directors' Deferral Plan, to be settled in Eli Lilly common stock after he separates from board service. This is a routine director compensation transaction rather than an open-market purchase or sale.
Eli Lilly & Co director Ralph Alvarez reported an automatic stock-based compensation grant. On March 16, 2026, he acquired 12.553 shares of common stock at $989.12 per share as a grant or award, increasing his directly held position to 55,601.215 shares.
According to the company’s directors’ deferral plan, Alvarez elected to defer this award as stock units instead of cash compensation, to be settled in common shares after he leaves the board. The filing also shows an indirect holding of 758 shares held by a trust, for which he disclaims beneficial ownership beyond his economic interest.
Eli Lilly & Co executive Eric Dozier reported a bona fide gift of 481 shares of common stock. The gift was recorded at no stated price per share and is classified as a non-derivative disposition. After the gift, he holds 14,455.212 shares directly and 385.020 shares indirectly through a 401(k) plan.
ELI LILLY & Co director Gabrielle Sulzberger reported an equity award under the company’s director compensation program. On the reported date, she acquired 4.786 shares of common stock at a reference price of $1,036.05 per share through a grant or award transaction.
According to the footnote, she elected to defer this compensation into stock units under the Lilly Directors' Deferral Plan, to be settled in common shares after she separates from service. Following this award, her directly held common stock balance reported in this filing is 2,966.222 shares.
ELI LILLY & Co director Juan R. Luciano reported an acquisition of 15.363 shares of common stock at $1,036.05 per share through a grant or award. At his election, this compensation was deferred into stock units under the Lilly Directors' Deferral Plan and will be settled in shares after his separation from service. Following this award, he directly owns 16,772.019 shares of common stock.
ELI LILLY & Co director J. Erik Fyrwald reported an equity award tied to his board compensation. On the reported date, he acquired 9.572 shares of common stock at a reference price of $1,036.05 per share, bringing his directly held total to 75,120.322 shares. According to the disclosure, he elected to defer this award into stock units under the Lilly Directors' Deferral Plan, to be settled in shares of common stock after he separates from board service.
ELI LILLY & Co director Ralph Alvarez reported an equity award tied to his board compensation. He acquired 11.985 shares of common stock on February 17, 2026 at a reference price of $1,036.05 per share as a grant, bringing his directly held stake to 55,491.627 shares.
According to the disclosure, he elected to defer this compensation into stock units under the Lilly Directors' Deferral Plan, which will be settled in common shares after he leaves board service. The filing also reports 758 shares held indirectly by a trust, with Alvarez disclaiming beneficial ownership beyond his economic interest.
ELI LILLY & Co SVP Donald A. Zakrowski exercised restricted stock units and had shares withheld for taxes. On the transaction date, 184 restricted stock units were converted into 184 common shares at $0.00 per share. To satisfy tax obligations, 81.553 common shares were disposed of at $1040.00 per share, leaving 3,525.89 directly owned shares and 1,728.57 common shares held indirectly through a 401(k) plan. Each restricted stock unit represents a contingent right to receive one share of common stock.
Eli Lilly & Co EVP & CFO Montarce Lucas reported equity award activity involving company stock. Lucas exercised or converted 368 restricted stock units, receiving the same number of Eli Lilly common shares. To cover tax obligations, 159.733 common shares were disposed of in a tax-withholding transaction at $1040 per share, leaving 16,258.473 common shares owned directly after these transactions.
Eli Lilly & Co executive Kenneth L. Custer reported routine equity transactions. On February 16, he exercised 207 restricted stock units, receiving 207 shares of common stock at no cost. On the same date, 91.311 shares were disposed of at $1,040 per share to satisfy tax withholding obligations, leaving him with 10,140.544 directly owned shares.
Adrienne S. Brown, EVP and President of Lilly Immunology at Eli Lilly & Co, exercised restricted stock units into common shares and had shares withheld to cover taxes. On the transaction date, 391 restricted stock units were converted into 391 shares of common stock at a stated price of $0.0000 per share.
Following this derivative exercise/conversion, a tax-withholding disposition of 169.966 common shares was reported at $1040.0000 per share to satisfy tax obligations. After these transactions, Brown directly owned 5,142.342 shares of Eli Lilly common stock.
Eli Lilly executive insider filing shows a corrected share adjustment. On February 9, 2026, the reporting officer (EVP & CIDO) is shown as having acquired 4,599.164 shares of Eli Lilly common stock at $1,044.67 per share. After this adjustment, the executive directly owns 26,396.534 shares. The accompanying note explains this amended Form 4 corrects an earlier over-withholding of shares for tax obligations caused by an administrative error.
Eli Lilly & Co senior vice president, finance, and chief accounting officer Donald A. Zakrowski acquired additional company equity on February 9, 2026. He received 583.784 shares of common stock as a grant or award at $1,044.67 per share, bringing his directly held common stock to 3,423.443 shares.
He also received a grant of 199.472 restricted stock units, each representing a contingent right to one share of common stock, with both exercisable and expiration dates of February 16, 2029. In addition, 1,728.57 common shares are held indirectly through a 401(k) plan.
Eli Lilly executive Ilya Yuffa reported an acquisition of company stock through an equity award. On 02/09/2026, he received 4,162.504 shares of Eli Lilly common stock in a grant or other acquisition at a price of $1,044.67 per share. Following this award, he directly holds 32,304.111 shares of Eli Lilly common stock as EVP & President, LLY USA & Global Capabilities.
Eli Lilly executive Jacob Van Naarden, EVP and President of LLY Oncology & Head of Corporate Business Development, acquired 4,865.888 shares of Eli Lilly common stock on February 9, 2026 through a grant or award at $1,044.67 per share. Following this award, he directly holds 26,626.498 common shares. He also has indirect holdings of 4,342 shares through the Van Naarden Family Trust and 5,302 shares through a spousal lifetime access trust. The transactions are reported with a disclaimer that he only beneficially owns the securities to the extent of his pecuniary interest, and a footnote explains a February 5, 2026 transfer of 5,302 spouse-held shares into the spousal lifetime access trust, including 1,000 shares previously misreported as directly held.